In his editorial, Dr. Clifford Hudis writes: "This multigene assay is unlikely to be the only test that can provide a prediction of chemotherapy benefit. A less expensive and broadly distributed test would be valuable globally. For now, however, this assay is the most rigorously tested option and provides proof of the principle that we can develop reproducible predictive tests to select patients who should not receive chemotherapy. In that regard, it is one more step toward precision. There are more steps ahead."
Over the past 8 days, we've discussed some of these potential 'next steps ahead' including gaining more clarity within the RS 11-17 group - this may arise following the completion of the TAILORx trial.
In your view, what are some even further 'next steps' toward predictive precision?
-
Like
Easy one-click social registration
Is this safe?We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.
ORWhy we require registering to vote
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.
Log in or create an account to comment
Social Login
Email Login
Log in via Email
Back to Social Login
Create Your Account